Cardiovascular drugs such as antiarrhythmic agents with Vaughan Williams class Ia action have been found to induce a sporadic hypoglycemia. Recent investigation has revealed that these drugs induce insulin secretion from pancreatic b-cells by inhibiting q Ž . ATP-sensitive K K channels in a manner similar to sulfonylurea drugs. The mechanism underlying block of K channels by ATP ATP antiarrhythmic drugs was different, however, from that of sulfonylureas: firstly, because binding of radioactive glibenclamide could not be inhibited by unlabelled antiarrhythmic agents, and vice versa; secondly, because the two compounds differ in the kinetics and sidedness of drug action-antiarrhythmic drugs act on the channel from the inner surface of the cell membrane, whereas glibenclamide binds through the intramembrane pathway; finally, it was shown that functional K channels in b-cells are composed of two distinct ATP Ž . molecules-a sulfonylurea receptor SUR and a channel pore-forming subunit, an inwardly-rectifying K channel with two transmem-Ž .
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Introduction
One of the undesired and peculiar side-effects of antiarrhythmic agents with Vaughan Williams class Ia action such as disopyramide and cibenzoline is that of sporadic w x hypoglycemia 1-8 . During antimalarial treatment with Ž quinine, an optical isomer of quinidine prototype of . Vaughan Williams class Ia antiarrhythmics , severe hypow x glycemic attacks have been reported 9,10 . Quinine has q Ž . been shown to block pancreatic ATP-sensitive K K ATP w x channels 11,12 . In some previous reports, an increased Ž . level of immunoreactive insulin IRI was associated with drug-induced hypoglycemia. The findings suggested that the compounds accelerate insulin secretion and thereby induce hypoglycemia. More recently, by applying patchclamp techniques to pancreatic b-cells along with receptor-binding assays and IRI measurements, they were found to reversibly inhibit pancreatic K channels and ATP promote insulin release, irrespective of blood sugar level w x 13-16 . In this brief review, we would like to summarize recent progress in the research of insulin secretion and its modulation by antiarrhythmic and sulfonylurea drugs.
The pancreatic K
channel is involved in the AT P glucose-sensor system and regulates insulin-secreting level Ž . The glucose transporter GLUT2 in the b-cell membrane works so efficiently that cytoplasmic glucose can attain a high enough level to be used as the principal fuel for mitochondrial ATP production. Thus, the activities of b-cell K channels can precisely reflect extracellular ATP sugar levels. In the late 1970s, by using radioactive Rb q w x efflux measurements, Henquin 24,25 demonstrated that glucose stimulation and tolbutamide, a prototype of the sulfonylurea drug, reduced K q conductance in rat pancreatic b-cells. Later, patch-clamp experiments revealed that this sulfonylurea-induced inhibition of K q currents was actually due to the closure of K channels. Ž thus increasing IRI from rat pancreatic islets 23.3 mM w x w x . 14 and 94.2 mM 16 , respectively . However, it has been reported that IRI was increased by as low as 6 mM of cibenzoline although the dose-response relation was not w x available in the report 34 . Assuming that these relatively high values are the same in humans, it is compatible with the clinical observation that hypoglycemia associated with these compounds occurs quite infrequently since therapeuw x tic concentrations are reported to be ; 1 mM 35 .
During the patch-clamp experiment using isolated bcells from rats, however, the IC values for blocking 50 K channels from outside the b-cell membrane were ATP lower than the concentrations needed to induce insulin Ž w x w x release 11 mM 14 for disopyramide and 5.2 mM 16 for . cibenzoline . In the cell-attached mode, alkalinization of extracellular medium containing cibenzoline increased its inhibitory action. The IC was reduced from 26.8 mM at 50 pH 6.2 to 0.9 mM at pH 8.4. In the inside-out mode, where the drug can get access to the binding site from the cytoplasmic side of the membrane, the compounds were 
The activities of K channels are known to be regu-ATP lated by intracellular ligands: ATP-dependent closure of the channel was re-opened by micromolar amounts of w x Ž . ADP 36,37 . In rat b-cells, ADP 100 mM was found to Ž . Ž recover cibenzoline 10 mM -, but not glibenclamide 1
. w x mM -induced block of channel activity 16 . These experimental results suggest that antiarrhythmic agents bind from Ž . the cytoplasmic side of the cell membrane Fig. 1 . This contrasts with the case of glibenclamide which has been w xŽ assumed to act via an intramembrane pathway 38,39 
The binding site of antiarrhythmic agents is distinct from SUR
The cibenzoline block was enhanced by alkalinization w x 16 . Since the p K a value for cibenzoline is 10.6, a 10-fold Ž . change of alkalinization at pH -10.6 produces a 10-fold Ž . higher concentration of the uncharged non-ionized form of the compound, which can more easily permeate the cell w x membrane than the charged form 40 . The drug thus appeared to reach the binding site on the inner side via a Ž . membrane pathway. In the receptor-binding assay Fig. 2 , w 3 x we found that the binding of H glibenclamide to pancreatic islets was inhibited by glibenclamide but not by w 3 x cibenzoline. In contrast, H cibenzoline binding was displaced by unlabelled cibenzoline but not by glibenclamide w x 16 .
During the whole-cell mode of patch-clamp experiments using Kir6.1-transfected NIH3T3 cells, we found that these antiarrhythmic agents reversibly blocked the K q Ž conductance carried by Kir6.1 channels IC for cibenzo-
50
. line is ; 12 mM, Fig. 2B . Glibenclamide, however, was Ž . unable to affect the conductance data not shown . These lines of experimental results suggest that the binding site w x for antiarrhythmic drugs is distinct from SUR 29 , but is Ž . probably the channel pore itself Kir6.2 .
Clinical implications
w x According to the clinical literature 1-8 , antiarrhythmic-drug-induced hypoglycemia appears to be associated with hypoalbuminemia, renal insufficiency or diabetes mellitus, especially in elderly patients. Therefore, special care should be paid to elderly diabetic patients who are already receiving sulfonylureas because renal dysfunction is one of the most common complications in this cohort of patients. The insulinotrophic effect of antiarrhythmic agents may be additional to the action of sulfonylurea drugs because these compounds act in a different manner through distinct receptors.
Ž .
w 3 x Ž . w 3 x Ž . It is known that patients on long-term therapy with a Ž sulfonylurea develop tolerance to the drug 'secondary' w x. sulfonylurea failure 41 . In the experimental setting, the continued presence of metabolic stress has been shown to abolish the inhibitory action of glibenclamide on cardiac w x K channels 42 . These findings are correlated with a ATP dissociation between SUR and channel pore-forming subunits. Thus, drug development based on antiarrhythmic drugs may help produce a new class of insulinotrophic agents which directly act on the channels. 
